{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:51:28Z","timestamp":1792014688713,"version":"4.4.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jtocrr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JTO Clinical and Research Reports"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jtocrr.2026.101038","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T23:45:45Z","timestamp":1782863145000},"page":"101038","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Living With ALK Fusion-Positive NSCLC: A French Nationwide Survey of the Psychosocial Impact Among Patients, Caregivers, and Health Care Professionals"],"prefix":"10.1016","volume":"7","author":[{"given":"Jacques","family":"Cadranel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Corre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy","family":"Roget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wingler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Alliaume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Bausson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Capdevielle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Mogenet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Mennecier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtocrr.2026.101038_bib1","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1158\/1078-0432.CCR-13-0318","article-title":"ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer","volume":"19","author":"Gainor","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtocrr.2026.101038_bib2","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1158\/1078-0432.CCR-08-0168","article-title":"EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer","volume":"14","author":"Koivunen","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtocrr.2026.101038_bib3","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/cncr.24181","article-title":"The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS","volume":"115","author":"Wong","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.jtocrr.2026.101038_bib4","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","article-title":"Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer","volume":"363","author":"Kwak","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtocrr.2026.101038_bib5","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtocrr.2026.101038_bib6","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/COC.0000000000000508","article-title":"Anaplastic lymphoma kinase (ALK)-positive tumors: clinical, radiographic and molecular profiles, and uncommon sites of metastases in patients with lung adenocarcinoma","volume":"42","author":"Gupta","year":"2019","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.jtocrr.2026.101038_bib7","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtocrr.2026.101038_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1566816","article-title":"Treatment of metastatic ALK-positive non-small cell lung cancer: indirect comparison of different ALK inhibitors using reconstructed patient data","volume":"15","author":"Damuzzo","year":"2025","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtocrr.2026.101038_bib9","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtocrr.2026.101038_bib10","article-title":"Targeting ALK rearrangements in NSCLC: current state of the art","volume":"12","author":"Peng","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtocrr.2026.101038_bib11","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.jtho.2021.07.035","article-title":"Brigatinib versus crizotinib in ALK inhibitor-naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial","volume":"16","author":"Camidge","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2026.101038_bib12","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtocrr.2026.101038_bib13","doi-asserted-by":"crossref","DOI":"10.1177\/17588359251316200","article-title":"Comparative analysis of alectinib and brigatinib in real-world treatment of advanced NSCLC with ALK rearrangements","volume":"17","author":"Kim","year":"2025","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.jtocrr.2026.101038_bib14","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000041506","article-title":"A comparative evaluation of alectinib for ALK-positive non-small-cell lung cancer: a systematic review","volume":"104","author":"Kharat","year":"2025","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jtocrr.2026.101038_bib15","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.21037\/tlcr-22-619","article-title":"Advancements of ALK inhibition of non-small cell lung cancer: a literature review","volume":"12","author":"Zia","year":"2023","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.jtocrr.2026.101038_bib16","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1200\/JCO.24.00581","article-title":"Lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer: 5-year outcomes from the phase III CROWN study","volume":"42","author":"Solomon","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtocrr.2026.101038_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21037\/tlcr-24-903","article-title":"Lorlatinib in frontline treatment of advanced ALK-positive non-small cell lung cancer: a highly efficient new standard of care but still challenging to manage","volume":"14","author":"Wespiser","year":"2025","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.jtocrr.2026.101038_bib18","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","article-title":"Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study","volume":"31","author":"Mok","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtocrr.2026.101038_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100612","article-title":"Clinical experience and management of adverse events in patients with advanced ALK-positive non-small-cell lung cancer receiving alectinib","volume":"7","author":"Dziadziuszko","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.jtocrr.2026.101038_bib20","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.lungcan.2021.03.005","article-title":"Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor-naive ALK+ non-small cell lung cancer (ALTA-1L)","volume":"155","author":"Garcia Campelo","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtocrr.2026.101038_bib21","doi-asserted-by":"crossref","first-page":"5171","DOI":"10.1158\/1078-0432.CCR-16-1293","article-title":"FDA approval: alectinib for the treatment of metastatic, ALK-positive non-small cell lung cancer following crizotinib","volume":"22","author":"Larkins","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtocrr.2026.101038_bib22","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/s41571-023-00844-0","article-title":"Lung cancer in patients who have never smoked - an emerging disease","volume":"21","author":"LoPiccolo","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jtocrr.2026.101038_bib23","first-page":"93","article-title":"Age and smoking intensity in non-small cell lung cancer patients with the anaplastic lymphoma kinase fusion gene","volume":"29","author":"Maezawa","year":"2025","journal-title":"Contemp Oncol (Pozn)"},{"key":"10.1016\/j.jtocrr.2026.101038_bib24","doi-asserted-by":"crossref","first-page":"LMT68","DOI":"10.2217\/lmt-2023-0013","article-title":"Lung cancer patients with anaplastic lymphoma kinase rearrangement lose affiliation with labor market at diagnosis","volume":"13","author":"Andersen","year":"2024","journal-title":"Lung Cancer Manag"},{"key":"10.1016\/j.jtocrr.2026.101038_bib25","article-title":"Humanistic burden of living with anaplastic lymphoma kinase-positive non-small-cell lung cancer: findings from the ALKConnect patient insight network and research platform","volume":"10","author":"Lin","year":"2020","journal-title":"Lung Cancer Manag"},{"key":"10.1016\/j.jtocrr.2026.101038_bib26","doi-asserted-by":"crossref","first-page":"e555","DOI":"10.1634\/theoncologist.2019-0463","article-title":"Physical activity and exercise in lung cancer care: will promises be fulfilled?","volume":"25","author":"Avancini","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.jtocrr.2026.101038_bib27","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1007\/s11764-016-0554-3","article-title":"Cancer survivors\u2019 experiences with insurance, finances, and employment: results from a multisite study","volume":"10","author":"Nekhlyudov","year":"2016","journal-title":"J Cancer Surviv"},{"key":"10.1016\/j.jtocrr.2026.101038_bib28","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.lungcan.2019.03.010","article-title":"Lung cancer survivors and employment: a systematic review","volume":"131","author":"Vayr","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtocrr.2026.101038_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-032639","article-title":"Unmet needs and opportunities for improving care for patients with advanced lung cancer on targeted therapies: a qualitative study","volume":"10","author":"Al Achkar","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.jtocrr.2026.101038_bib30","article-title":"Unmet supportive care needs associated with quality of life for people with lung cancer: a systematic review of the evidence 2007\u20132020","volume":"31","author":"Cochrane","year":"2022","journal-title":"Eur J Cancer Care (Engl)"},{"key":"10.1016\/j.jtocrr.2026.101038_bib31","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2147\/JMDH.S482232","article-title":"Unmet supportive care needs of lung cancer survival patients at different cancer stages and treatment phases","volume":"18","author":"Lee","year":"2025","journal-title":"J Multidiscip Healthc"},{"key":"10.1016\/j.jtocrr.2026.101038_bib32","doi-asserted-by":"crossref","DOI":"10.1002\/pon.6313","article-title":"Supporting the support person: oncologists\u2019 roles in reducing support people\u2019s uncertainty and facilitating psychological adjustment","volume":"33","author":"Broadbridge","year":"2024","journal-title":"Psychooncology"},{"key":"10.1016\/j.jtocrr.2026.101038_bib33","first-page":"246","article-title":"Results of the qualitative phase of the national survey \u201cLiving with your ALK+ cancer\u201d on societal issues in ALK+ NSCLC [CPLF abstract: 467; in French]","volume":"17","author":"Cadranel","year":"2025","journal-title":"Rev Malad Respir Actual"},{"key":"10.1016\/j.jtocrr.2026.101038_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107919","article-title":"Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer","volume":"195","author":"Bauman","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtocrr.2026.101038_bib35","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1080\/14796694.2025.2489319","article-title":"Order of treatment with ALK inhibitors and its effect on people with lung cancer in the real world: a plain language summary","volume":"21","author":"Bauman","year":"2025","journal-title":"Future Oncol"},{"key":"10.1016\/j.jtocrr.2026.101038_bib36","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s12889-024-17669-w","article-title":"Does caring for patients with advanced non-small cell lung cancer affect health-related quality of life of caregivers? A multicenter, cross-sectional study","volume":"24","author":"Yang","year":"2024","journal-title":"BMC Public Health"},{"key":"10.1016\/j.jtocrr.2026.101038_bib37","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1200\/JCO.22.00859","article-title":"Lorlatinib in frontline therapy for ALK+ advanced non-small-cell lung cancer: still a matter of debate?","volume":"40","author":"P\u00e9rol","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtocrr.2026.101038_bib38","article-title":"Quality of life and role of palliative and supportive care for patients with brain metastases and caregivers: a review","volume":"13","author":"Wu","year":"2022","journal-title":"Front Neurol"},{"key":"10.1016\/j.jtocrr.2026.101038_bib39","doi-asserted-by":"crossref","DOI":"10.57264\/cer-2024-0111","article-title":"A systematic review of health-related quality of life outcomes in patients with advanced breast cancer treated with palbociclib","volume":"13","author":"Samjoo","year":"2024","journal-title":"J Comp Eff Res"},{"key":"10.1016\/j.jtocrr.2026.101038_bib40","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1159\/000542562","article-title":"Real-world experience in the management of chronic myeloid leukemia patients focused on tyrosine kinase inhibitors intolerance and health-related quality of life","volume":"148","author":"Moon","year":"2025","journal-title":"Acta Haematol"},{"key":"10.1016\/j.jtocrr.2026.101038_bib41","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/pon.6183","article-title":"Improving quality of life and symptom experience in patients with metastatic breast cancer: a systematic review of supportive care interventions","volume":"32","author":"Keane","year":"2023","journal-title":"Psychooncology"}],"container-title":["JTO Clinical and Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364326000895?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364326000895?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:20:55Z","timestamp":1792012855000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666364326000895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2666364326000895"],"URL":"https:\/\/doi.org\/10.1016\/j.jtocrr.2026.101038","relation":{},"ISSN":["2666-3643"],"issn-type":[{"value":"2666-3643","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Living With ALK Fusion-Positive NSCLC: A French Nationwide Survey of the Psychosocial Impact Among Patients, Caregivers, and Health Care Professionals","name":"articletitle","label":"Article Title"},{"value":"JTO Clinical and Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtocrr.2026.101038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"101038"}}